Targepeutics
Targeted immunotherapy for brain cancer
Hummelstown, Pennsylvania, US
Targepeutics is a biopharmaceutical company specializing in the development of molecularly targeted therapeutics for aggressive brain cancers.
Problem Statement
Aggressive brain cancers like glioblastoma (GBM) in adults and diffuse midline glioma (DMG) in children are uniformly fatal with little change in survival rates for decades. There is a dire need for new and effective therapies.
Core Technology
Molecularly targeted therapeutics
Key Differentiators
Focuses on selectively destroying cancer cells with minimal damage to normal cells.
Clinical Focus
Oncology
Company Info
- Business Model
- Licensing
- Total Funding
- 605,000
- Website
- www.targepeutics.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
FDA Rare Pediatric Disease Designation (2025); Orphan Drug Designation for glioblastoma and DIPG; IL-13Rα2 mechanism shows 78-83% receptor expression in target tumors; preclinical evidence demonstrates apoptosis induction and radiotherapy synergy in mouse models. IND filing Q1 2026.
MedStartr Index Score
?What do you think of Targepeutics?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.